Align Technology, Inc. - Common Stock (ALGN)

Align Technology's fourth quarter was met with a positive market response, as management pointed to strong growth in clear aligner volumes and continued momentum within dental service organizations (DSOs). CEO Joe Hogan highlighted that the improved results were driven by record case volumes in Europe, Latin America, and Asia-Pacific, with DSOs in the Americas delivering double-digit year-over-year growth. Hogan noted the company's broadening product portfolio and targeted marketing strategies, which supported both adult and teen patient segments, as key factors behind the volume gains.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Align Technology, Inc. (NASDAQ: ALGN) stock rose on Thursday after reporting Q4 earnings beating expectations.

Dental technology company Align Technology (NASDAQ:ALGN) announced better-than-expected revenue in Q4 CY2025, with sales up 5.3% year on year to $1.05 billion. The company expects next quarter’s revenue to be around $1.02 billion, close to analysts’ estimates. Its non-GAAP profit of $3.29 per share was 10.8% above analysts’ consensus estimates.

Align Tech (ALGN) Q4 2025 Earnings Call Transcript

Dental technology company Align Technology (NASDAQ:ALGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5.3% year on year to $1.05 billion. The company expects next quarter’s revenue to be around $1.02 billion, close to analysts’ estimates. Its non-GAAP profit of $3.29 per share was 10.8% above analysts’ consensus estimates.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'25") and year ended December 31, 2025 ("2025"). Q4'25 total revenues were $1,047.6 million, up 5.2% sequentially and up 5.3% year-over-year. Q4'25 total revenues were unfavorably impacted by foreign exchange of approximately $3.0 million or 0.3% sequentially and favorably impacted by approximately $14.8 million or 1.4% year-over-year.(1) Q4'25 Clear Aligner revenues were $838.1 million, up 4.0% sequentially and up 5.5% year-over-year. Q4'25 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $2.3 million or 0.3% sequentially and favorably impacted by approximately $12.4 million or 1.5% year-over-year.(1) Q4'25 Clear Aligner volume of 676.9 thousand cases was up 4.5% sequentially and up 7.7% year-over-year. Q4'25 Imaging Systems and CAD/CAM Services revenues were $209.4 million, up 10.3% sequentially and up 4.2% year-over-year. Q4'25 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $0.7 million or 0.3% sequentially and favorably impacted by approximately $2.5 million or 1.2% year-over-year.(1)

Dental technology company Align Technology (NASDAQ:ALGN) will be reporting results this Wednesday after the bell. Here’s what investors should know.

Align Technology, Inc. (NASDAQ: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced its collaboration with the University of Bern on Switzerland’s first Swiss Oral Health Study – an epidemiological initiative led by Professor Dr. Hendrik Meyer-Lückel, director of the Clinic for Conservative, Preventive, and Pediatric Dentistry at the University of Bern.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Over the last six months, Align Technology’s shares have sunk to $170.94, producing a disappointing 14.2% loss - a stark contrast to the S&P 500’s 11.3% gain. This might have investors contemplating their next move.

Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement of Orthodontics (CFAO). Under this initiative, Align has committed to support Invisalign treatment for 30 eligible patients through CFAO’s Smiles4Canada program, a public health goodwill program founded in 2016 to put a smile, both figuratively and literally, on a young person with significant orthodontic needs, whose family does not have the financial resources to pay for the procedure.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 13.5% return has closely followed the S&P 500.

Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today shared highlights from its participation at the Greater New York Dental Meeting (GNYDM) 2025, one of the largest annual dental congresses in the United States.

Check out the companies making headlines this week:

Check out the companies making headlines yesterday: